查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1269443

放射性醫藥品治療診斷市場- 全球產業分析，規模，佔有率，成長，趨勢，預測，2023-2031年

Radiopharmaceutical Theranostics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 226 Pages | 商品交期: 2-10個工作天內

價格

放射性醫藥品治療診斷市場- 調查範圍:

TMR 的研究報告《全球放射性醫藥品治療診斷市場》為了提供2023年～2031年預測期間上關於市場指標的寶貴知識和見解，不僅探討了過去的增長趨勢，還調查了當前的增長趨勢和機會。本報告以 2023 年為基準年，2031 年為預測年。提供2017年到2031年的全球放射性醫藥品治療診斷市場收益。並刊載2023年2031年的全球放射性醫藥品治療診斷市場年複合成長率。

本報告透過廣泛研究作成。初步研究中由分析師對主要意見領袖、行業領袖和輿論製造者進行訪談，並進行大部分研究工作。二次研究則參考主要公司的產品資料、年報、新聞稿和相關文件，來掌握放射性醫藥品治療診斷市場。

該報告深入探討全球放射性醫藥品治療診斷市場的競爭格局。鎖定全球放射性醫藥品治療診斷市場活動的主要企業，並對每家公司進行了不同屬性的分析。介紹企業概要，財務狀況，最近的趨勢，SWOT等全球放射性醫藥品治療診斷市場企業的屬性。

目錄

第1章 序文

  • 市場定義和規模
  • 市場區隔
  • 主要的調查目的
  • 調查亮點

第2章 前提條件與調查手法

第3章 摘要整理:全球市場

第4章 市場概要

  • 簡介
    • 定義
    • 產業的演進與發展
  • 概要
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 機會
  • 全球市場的分析與預測，2017-2031年
    • 市場收益預測

第5章 主要洞察

  • 法律規章方案
  • 主要的流通策略
  • 價格設定相關分析
  • 放射性描繪器相關專利
  • 放射性描繪器的技術的進步
  • 放射性描繪器的種類- 概要
  • COVID-19疫情對產業的影響

第6章 全球市場分析·預測:放射性同位元素

  • 簡介和定義
  • 主要調查結果/發展情形
  • 市場價值預測:放射性同位元素，2017-2031年
    • Technetium-99
    • 鎵-68
    • 碘-131
    • 鐳-223
    • 氟-18
    • 釔-90
    • 鎦-177
    • 銅-67&64
    • 釤-153
    • 其他
  • 市場魅力分析:放射性同位元素

第7章 全球市場分析·預測:各應用領域

  • 簡介&定義
  • 主要調查結果/發展情形
  • 市場價值預測:各應用領域，2017-2031年
    • 腫瘤學
    • 心臟病
    • 其他
  • 市場魅力分析:各應用領域

第8章 全球市場分析·預測:各來源

  • 簡介&定義
  • 主要調查結果/發展情形
  • 市場價值預測:各來源，2017-2031年
    • 核子反應爐
    • 迴旋加速器
  • 市場魅力分析:各來源

第9章 全球市場分析·預測:方法

  • 簡介和定義
  • 主要調查結果/發展情形
  • 市場價值預測:方法，2017年～2031年
    • 標靶治療藥(Rx)
    • 伴隨式診斷藥(DX)
  • 市場魅力分析:方法

第10章 全球市場分析·預測:放射性描繪器各類型

  • 簡介和定義
  • 主要調查結果/發展情形
  • 市場價值預測:放射性描繪器各類型，2017-2031年
    • [月太]性
    • 非[月太]性
  • 市場魅力分析:無線電描繪器各類型

第11章 全球市場分析·預測:各終端用戶

  • 簡介&定義
  • 主要調查結果/發展情形
  • 市場規模預測:各終端用戶，2017年～2031年
    • 醫院
    • 學術·研究機關
    • 其他
  • 市場魅力分析:各終端用戶

第12章 全球市場分析·預測:各地區

  • 主要調查結果
  • 市場價值預測:各地區，2017-2031年
    • 美國
    • 歐洲
    • 全球其他地區
  • 市場魅力分析:各地區

第13章 美國市場分析·預測

  • 簡介
    • 主要調查結果
  • 市場規模預測:放射性同位元素，2017年～2031年
    • Technetium-99
    • 鎵-68
    • 碘-131
    • 鐳-223
    • 氟-18
    • 釔-90
    • 鎦-177
    • 銅-67&64
    • 釤-153
    • 其他
  • 市場價值預測:各應用領域，2017-2031年
    • 腫瘤學
    • 心臟病
    • 其他
  • 市場價值預測:供給來源，2017-2031年
    • 核子反應爐
    • 迴旋加速器
  • 市場價值預測:方法，2017-2031年
    • 標靶治療藥(Rx)
    • 伴隨式診斷藥(DX)
  • 市場價值預測:放射性描繪器各類型，2017-2031年
    • [月太]性
    • 非[月太]性
  • 市場價值預測:各終端用戶，2017-2031年
    • 醫院
    • 學術·研究機關
    • 其他
  • 市場魅力分析
    • 放射性同位元素
    • 各用途
    • 供給來源
    • 方法
    • 放射性描繪器各類型
    • 各終端用戶

第14章 歐洲市場分析與預測

  • 簡介
    • 主要調查結果
  • 市場價值預測:放射性同位元素，2017-2031年
    • Technetium-99
    • 鎵-68
    • 碘-131
    • 鐳-223
    • 氟-18
    • 釔-90
    • 鎦-177
    • 銅-67&64
    • 釤-153
    • 其他
  • 市場價值預測:各應用領域，2017-2031年
    • 腫瘤學
    • 心臟病
    • 其他
  • 市場價值預測:供給來源，2017-2031年
    • 核子反應爐
    • 迴旋加速器
  • 市場價值預測:方法，2017-2031年
    • 標靶治療藥(Rx)
    • 伴隨式診斷藥(DX)
  • 市場價值預測:放射性描繪器各類型，2017-2031年
    • [月太]性
    • 非[月太]性
  • 市場價值預測:各終端用戶，2017-2031年
    • 醫院
    • 學術·研究機關
    • 其他
  • 市場價值預測:國家·小各地區，2017-2031年
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他歐洲
  • 市場魅力分析
    • 放射性同位元素
    • 各應用領域
    • 各來源
    • 方法
    • 放射性描繪器各類型
    • 各終端用戶
    • 各國/輔助region

第15章 全球其他地區的市場分析與預測

  • 簡介
    • 主要的調查結果
  • 市場價值預測:放射性同位元素，2017年～2031年
    • Technetium-99
    • 鎵-68
    • 碘-131
    • 鐳-223
    • 氟-18
    • 釔-90
    • 鎦-177
    • 銅-67&64
    • 釤-153
    • 其他
  • 市場價值預測:各應用領域，2017-2031年
    • 腫瘤學
    • 心臟病
    • 其他
  • 市場價值預測:供給來源，2017-2031年
    • 核子反應爐
    • 迴旋加速器
  • 市場價值預測:方法，2017-2031年
    • 標靶治療藥(Rx)
    • 伴隨式診斷藥(DX)
  • 市場價值預測:放射性描繪器各類型，2017-2031年
    • [月太]性
    • 非[月太]性
  • 市場價值預測:各終端用戶，2017-2031年
    • 醫院
    • 學術·研究機關
    • 其他
  • 市場魅力分析
    • 放射性同位元素
    • 各用途
    • 供給來源
    • 方法
    • 放射性描繪器各類型
    • 各終端用戶

第16章 競爭情形

  • 市場競爭矩陣(企業各層級，不同企業規模)
  • 市場佔有率分析:各企業(2022年)
  • 企業簡介
    • Advanced Accelerator Applications(Novartis AG)
    • Aurobindo Pharma
    • Bayer AG
    • Blue Earth Diagnostics(Bracco)
    • Cardinal Health
    • Clarity Pharmaceuticals
    • GE Healthcare
    • Jubliant Radiopharma
    • Lantheus Medical Imaging
    • Navidea Biopharmaceuticals, Inc.
    • SOFIE
    • Telix Pharmaceuticals
Product Code: TMRGL82604

Radiopharmaceutical Theranostics Market - Scope of Report:

TMR's report on the global radiopharmaceutical theranostics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global radiopharmaceutical theranostics market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global radiopharmaceutical theranostics market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the radiopharmaceutical theranostics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global radiopharmaceutical theranostics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global radiopharmaceutical theranostics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global radiopharmaceutical theranostics market.

The report delves into the competitive landscape of the global radiopharmaceutical theranostics market. Key players operating in the global radiopharmaceutical theranostics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global radiopharmaceutical theranostics market profiled in this report.

Key Questions Answered in Global Radiopharmaceutical Theranostics Market Report:

  • What is the sales/revenue generated by radiopharmaceutical theranostics across all regions during the forecast period?
  • What are the opportunities in the global radiopharmaceutical theranostics market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Radiopharmaceutical Theranostics Market - Research Objectives and Research Approach:

The comprehensive report on the global radiopharmaceutical theranostics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global radiopharmaceutical theranostics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global radiopharmaceutical theranostics market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Radiopharmaceutical Theranostics Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, 2017-2031
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Regulatory Scenario
  • 5.2. Key Distribution Strategies
  • 5.3. Pricing Analysis
  • 5.4. Patents on Radiotracers
  • 5.5. Technological Advancements in Radiopharmaceutical Theranostics
  • 5.6. Radiotracer Type - Overview
  • 5.7. COVID-19 Pandemic Impact on Industry

6. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Radioisotope

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Radioisotope, 2017-2031
    • 6.3.1. Technetium-99
    • 6.3.2. Gallium-68
    • 6.3.3. Iodine-131
    • 6.3.4. Radium-223
    • 6.3.5. Fluorine-18
    • 6.3.6. Yttrium-90
    • 6.3.7. Lutetium-177
    • 6.3.8. Copper-67 & 64
    • 6.3.9. Samarium-153
    • 6.3.10. Others
  • 6.4. Market Attractiveness Analysis, by Radioisotope

7. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Application

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Application, 2017-2031
    • 7.3.1. Oncology
    • 7.3.2. Cardiology
    • 7.3.3. Others
  • 7.4. Market Attractiveness Analysis, by Application

8. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Source

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Source, 2017-2031
    • 8.3.1. Nuclear Reactors
    • 8.3.2. Cyclotrons
  • 8.4. Market Attractiveness Analysis, by Source

9. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Approach

  • 9.1. Introduction & Definition
  • 9.2. Key Findings/Developments
  • 9.3. Market Value Forecast, by Approach, 2017-2031
    • 9.3.1. Targeted Therapeutic (Rx)
    • 9.3.2. Companion Diagnostic (DX)
  • 9.4. Market Attractiveness Analysis, by Approach

10. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Radiotracer Type

  • 10.1. Introduction & Definition
  • 10.2. Key Findings/Developments
  • 10.3. Market Value Forecast, by Radiotracer Type, 2017-2031
    • 10.3.1. Peptidic
    • 10.3.2. Non-peptidic
  • 10.4. Market Attractiveness Analysis, by Radiotracer Type

11. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by End-user

  • 11.1. Introduction & Definition
  • 11.2. Key Findings/Developments
  • 11.3. Market Value Forecast, by End-user, 2017-2031
    • 11.3.1. Hospitals
    • 11.3.2. Academic & Research Institutes
    • 11.3.3. Others
  • 11.4. Market Attractiveness Analysis, by End-user

12. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Region

  • 12.1. Key Findings
  • 12.2. Market Value Forecast, by Region, 2017-2031
    • 12.2.1. U.S.
    • 12.2.2. Europe
    • 12.2.3. Rest of the World
  • 12.3. Market Attractiveness Analysis, by Region

13. U.S. Radiopharmaceutical Theranostics Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Radioisotope, 2017-2031
    • 13.2.1. Technetium-99
    • 13.2.2. Gallium-68
    • 13.2.3. Iodine-131
    • 13.2.4. Radium-223
    • 13.2.5. Fluorine-18
    • 13.2.6. Yttrium-90
    • 13.2.7. Lutetium-177
    • 13.2.8. Copper-67 & 64
    • 13.2.9. Samarium-153
    • 13.2.10. Others
  • 13.3. Market Value Forecast, by Application, 2017-2031
    • 13.3.1. Oncology
    • 13.3.2. Cardiology
    • 13.3.3. Others
  • 13.4. Market Value Forecast, by Source, 2017-2031
    • 13.4.1. Nuclear Reactors
    • 13.4.2. Cyclotrons
  • 13.5. Market Value Forecast, by Approach, 2017-2031
    • 13.5.1. Targeted Therapeutic (Rx)
    • 13.5.2. Companion Diagnostic (DX)
  • 13.6. Market Value Forecast, by Radiotracer Type, 2017-2031
    • 13.6.1. Peptidic
    • 13.6.2. Non-peptidic
  • 13.7. Market Value Forecast, by End-user, 2017-2031
    • 13.7.1. Hospitals
    • 13.7.2. Academic & Research Institutes
    • 13.7.3. Others
  • 13.8. Market Attractiveness Analysis
    • 13.8.1. By Radioisotope
    • 13.8.2. By Application
    • 13.8.3. By Source
    • 13.8.4. By Approach
    • 13.8.5. By Radiotracer Type
    • 13.8.6. By End-user

14. Europe Radiopharmaceutical Theranostics Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Radioisotope, 2017-2031
    • 14.2.1. Technetium-99
    • 14.2.2. Gallium-68
    • 14.2.3. Iodine-131
    • 14.2.4. Radium-223
    • 14.2.5. Fluorine-18
    • 14.2.6. Yttrium-90
    • 14.2.7. Lutetium-177
    • 14.2.8. Copper-67 & 64
    • 14.2.9. Samarium-153
    • 14.2.10. Others
  • 14.3. Market Value Forecast, by Application, 2017-2031
    • 14.3.1. Oncology
    • 14.3.2. Cardiology
    • 14.3.3. Others
  • 14.4. Market Value Forecast, by Source, 2017-2031
    • 14.4.1. Nuclear Reactors
    • 14.4.2. Cyclotrons
  • 14.5. Market Value Forecast, by Approach, 2017-2031
    • 14.5.1. Targeted Therapeutic (Rx)
    • 14.5.2. Companion Diagnostic (DX)
  • 14.6. Market Value Forecast, by Radiotracer Type, 2017-2031
    • 14.6.1. Peptidic
    • 14.6.2. Non-peptidic
  • 14.7. Market Value Forecast, by End-user, 2017-2031
    • 14.7.1. Hospitals
    • 14.7.2. Academic & Research Institutes
    • 14.7.3. Others
  • 14.8. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.8.1. Germany
    • 14.8.2. U.K.
    • 14.8.3. France
    • 14.8.4. Italy
    • 14.8.5. Spain
    • 14.8.6. Rest of Europe
  • 14.9. Market Attractiveness Analysis
    • 14.9.1. By Radioisotope
    • 14.9.2. By Application
    • 14.9.3. By Source
    • 14.9.4. By Approach
    • 14.9.5. By Radiotracer Type
    • 14.9.6. By End-user
    • 14.9.7. By Country/Sub-region

15. Rest of the World Radiopharmaceutical Theranostics Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Radioisotope, 2017-2031
    • 15.2.1. Technetium-99
    • 15.2.2. Gallium-68
    • 15.2.3. Iodine-131
    • 15.2.4. Radium-223
    • 15.2.5. Fluorine-18
    • 15.2.6. Yttrium-90
    • 15.2.7. Lutetium-177
    • 15.2.8. Copper-67 & 64
    • 15.2.9. Samarium-153
    • 15.2.10. Others
  • 15.3. Market Value Forecast, by Application, 2017-2031
    • 15.3.1. Oncology
    • 15.3.2. Cardiology
    • 15.3.3. Others
  • 15.4. Market Value Forecast, by Source, 2017-2031
    • 15.4.1. Nuclear Reactors
    • 15.4.2. Cyclotrons
  • 15.5. Market Value Forecast, by Approach, 2017-2031
    • 15.5.1. Targeted Therapeutic (Rx)
    • 15.5.2. Companion Diagnostic (DX)
  • 15.6. Market Value Forecast, by Radiotracer Type, 2017-2031
    • 15.6.1. Peptidic
    • 15.6.2. Non-peptidic
  • 15.7. Market Value Forecast, by End-user, 2017-2031
    • 15.7.1. Hospitals
    • 15.7.2. Academic & Research Institutes
    • 15.7.3. Others
  • 15.8. Market Attractiveness Analysis
    • 15.8.1. By Radioisotope
    • 15.8.2. By Application
    • 15.8.3. By Source
    • 15.8.4. By Approach
    • 15.8.5. By Radiotracer Type
    • 15.8.6. By End-user

16. Competition Landscape

  • 16.1. Market Player Competition Matrix (by tier and size of companies)
  • 16.2. Market Share Analysis, by Company (2022)
  • 16.3. Company Profiles
    • 16.3.1. Advanced Accelerator Applications (Novartis AG)
      • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.1.2. Product Portfolio
      • 16.3.1.3. Financial Overview
      • 16.3.1.4. SWOT Analysis
      • 16.3.1.5. Strategic Overview
    • 16.3.2. Aurobindo Pharma
      • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.2.2. Product Portfolio
      • 16.3.2.3. Financial Overview
      • 16.3.2.4. SWOT Analysis
      • 16.3.2.5. Strategic Overview
    • 16.3.3. Bayer AG
      • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.3.2. Product Portfolio
      • 16.3.3.3. Financial Overview
      • 16.3.3.4. SWOT Analysis
      • 16.3.3.5. Strategic Overview
    • 16.3.4. Blue Earth Diagnostics (Bracco)
      • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.4.2. Product Portfolio
      • 16.3.4.3. Financial Overview
      • 16.3.4.4. SWOT Analysis
      • 16.3.4.5. Strategic Overview
    • 16.3.5. Cardinal Health
      • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.5.2. Product Portfolio
      • 16.3.5.3. Financial Overview
      • 16.3.5.4. SWOT Analysis
      • 16.3.5.5. Strategic Overview
    • 16.3.6. Clarity Pharmaceuticals
      • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.6.2. Product Portfolio
      • 16.3.6.3. Financial Overview
      • 16.3.6.4. SWOT Analysis
      • 16.3.6.5. Strategic Overview
    • 16.3.7. GE Healthcare
      • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.7.2. Product Portfolio
      • 16.3.7.3. Financial Overview
      • 16.3.7.4. SWOT Analysis
      • 16.3.7.5. Strategic Overview
    • 16.3.8. Jubliant Radiopharma
      • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.8.2. Product Portfolio
      • 16.3.8.3. Financial Overview
      • 16.3.8.4. SWOT Analysis
      • 16.3.8.5. Strategic Overview
    • 16.3.9. Lantheus Medical Imaging
      • 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.9.2. Product Portfolio
      • 16.3.9.3. Financial Overview
      • 16.3.9.4. SWOT Analysis
      • 16.3.9.5. Strategic Overview
    • 16.3.10. Navidea Biopharmaceuticals, Inc.
      • 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.10.2. Product Portfolio
      • 16.3.10.3. Financial Overview
      • 16.3.10.4. SWOT Analysis
      • 16.3.10.5. Strategic Overview
    • 16.3.11. SOFIE
      • 16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.11.2. Product Portfolio
      • 16.3.11.3. Financial Overview
      • 16.3.11.4. SWOT Analysis
      • 16.3.11.5. Strategic Overview
    • 16.3.12. Telix Pharmaceuticals
      • 16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.12.2. Product Portfolio
      • 16.3.12.3. Financial Overview
      • 16.3.12.4. SWOT Analysis
      • 16.3.12.5. Strategic Overview

List of Tables

  • Table 01: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radioisotope, 2017-2031
  • Table 02: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 03: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Source, 2017-2031
  • Table 04: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Approach, 2017-2031
  • Table 05: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radiotracer Type, 2017-2031
  • Table 06: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 07: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Country/Region, 2017-2031
  • Table 08: U.S. Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radioisotope, 2017-2031
  • Table 09: U.S. Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 10: U.S. Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Source, 2017-2031
  • Table 11: U.S. Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Approach, 2017-2031
  • Table 12: U.S. Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radiotracer Type, 2017-2031
  • Table 13: U.S. Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 14: Europe Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 15: Europe Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radioisotope, 2017-2031
  • Table 16: Europe Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 17: Europe Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Source, 2017-2031
  • Table 18: Europe Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Approach, 2017-2031
  • Table 19: EU Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radiotracer Type, 2017-2031
  • Table 20: EU Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 21: Rest of the World Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radioisotope, 2017-2031
  • Table 22: Rest of the World Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 23: Rest of the World Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Source, 2017-2031
  • Table 24: Rest of the World Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Approach, 2017-2031
  • Table 25: Rest of the World Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radiotracer Type, 2017-2031
  • Table 26: Rest of the World Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by End-user, 2017-2031

List of Figures

  • Figure 01: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Global Radiopharmaceutical Theranostics Market Value Share, by Radioisotope, 2022
  • Figure 03: Global Radiopharmaceutical Theranostics Market Value Share, by Application, 2022
  • Figure 04: Global Radiopharmaceutical Theranostics Market Value Share, by Source, 2022
  • Figure 05: Global Radiopharmaceutical Theranostics Market Value Share, by Approach, 2022
  • Figure 06: Global Radiopharmaceutical Theranostics Market Value Share, by End-user, 2022
  • Figure 07: Global Radiopharmaceutical Theranostics Market Value Share, by Radiotracer Type, 2022
  • Figure 08: Global Radiopharmaceutical Theranostics Market Value Share Analysis, by Radioisotope, 2022 and 2031
  • Figure 09: Global Radiopharmaceutical Theranostics Market Attractiveness Analysis, Radioisotope, 2023-2031
  • Figure 10: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Technetium-99, 2017-2031
  • Figure 11: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Gallium-68, 2017-2031
  • Figure 12: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Iodine-131, 2017-2031
  • Figure 13: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Radium-223, 2017-2031
  • Figure 14: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Fluorine-18, 2017-2031
  • Figure 15: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Yttrium-90, 2017-2031
  • Figure 16: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Lutetium-177, 2017-2031
  • Figure 17: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Copper-67 & 64, 2017-2031
  • Figure 18: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Samarium-153, 2017-2031
  • Figure 19: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Others, 2017-2031
  • Figure 20: Global Radiopharmaceutical Theranostics Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 21: Global Radiopharmaceutical Theranostics Market Attractiveness Analysis, Application, 2023-2031
  • Figure 22: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Oncology, 2017-2031
  • Figure 23: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Cardiology, 2017-2031
  • Figure 24: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Others, 2017-2031
  • Figure 25: Global Radiopharmaceutical Theranostics Market Value Share Analysis, by Source, 2022 and 2031
  • Figure 26: Global Radiopharmaceutical Theranostics Market Attractiveness Analysis, Source, 2023-2031
  • Figure 27: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Nuclear Reactors, 2017-2031
  • Figure 28: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Cyclotrons, 2017-2031
  • Figure 29: Global Radiopharmaceutical Theranostics Market Value Share Analysis, by Approach, 2022 and 2031
  • Figure 30: Global Radiopharmaceutical Theranostics Market Attractiveness Analysis, Approach, 2023-2031
  • Figure 31: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Targeted Therapeutic (Rx), 2017-2031
  • Figure 32: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Companion Diagnostic (DX), 2017-2031
  • Figure 33: Global Radiopharmaceutical Theranostics Market Value Share Analysis, by Radiotracer Type, 2022 and 2031
  • Figure 34: Global Radiopharmaceutical Theranostics Market Attractiveness Analysis, Radiotracer Type, 2023-2031
  • Figure 35: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Peptidic, 2017-2031
  • Figure 36: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Non-peptidic, 2017-2031
  • Figure 37: Global Radiopharmaceutical Theranostics Market Value Share Analysis, by End-user 2022 and 2031
  • Figure 38: Global Radiopharmaceutical Theranostics Market Attractiveness Analysis, End-user, 2023-2031
  • Figure 39: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Hospitals, 2017-2031
  • Figure 40: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Academic & Research Institutes, 2017-2031
  • Figure 41: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Others, 2017-2031
  • Figure 42: Global Radiopharmaceutical Theranostics Market Value Share Analysis, by Country/Region, 2022 and 2031
  • Figure 43: Global Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Country/Region, 2023-2031
  • Figure 44: U.S. Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 45: U.S. Radiopharmaceutical Theranostics Market Value Share Analysis, by Radioisotope, 2022 and 2031
  • Figure 46: U.S. Radiopharmaceutical Theranostics Market Attractiveness Analysis, Radioisotope, 2023-2031
  • Figure 47: U.S. Radiopharmaceutical Theranostics Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 48: U.S. Radiopharmaceutical Theranostics Market Attractiveness Analysis, Application, 2023-2031
  • Figure 49: U.S. Radiopharmaceutical Theranostics Market Value Share Analysis, by Source 2022, and 2031
  • Figure 50: U.S. Radiopharmaceutical Theranostics Market Attractiveness Analysis, Source, 2023-2031
  • Figure 51: U.S. Radiopharmaceutical Theranostics Market Value Share Analysis, by Approach, 2022 and 2031
  • Figure 52: U.S. Radiopharmaceutical Theranostics Market Attractiveness Analysis, Approach, 2023-2031
  • Figure 53: Global Radiopharmaceutical Theranostics Market Value Share Analysis, by Radiotracer Type, 2022 and 2031
  • Figure 54: Global Radiopharmaceutical Theranostics Market Attractiveness Analysis, Radiotracer Type, 2023-2031
  • Figure 55: Global Radiopharmaceutical Theranostics Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 56: Global Radiopharmaceutical Theranostics Market Attractiveness Analysis, End-user, 2023-2031
  • Figure 57: Europe Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 58: Europe Radiopharmaceutical Theranostics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 59: Europe Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 60: Europe Radiopharmaceutical Theranostics Market Value Share Analysis, by Radioisotope, 2022 and 2031
  • Figure 61: Europe Radiopharmaceutical Theranostics Market Attractiveness Analysis, Radioisotope, 2023-2031
  • Figure 62: Europe Radiopharmaceutical Theranostics Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 63: Europe Radiopharmaceutical Theranostics Market Attractiveness Analysis, Application, 2023-2031
  • Figure 64: Europe Radiopharmaceutical Theranostics Market Value Share Analysis, by Source, 2022 and 2031
  • Figure 65: Europe Radiopharmaceutical Theranostics Market Attractiveness Analysis, Source, 2023-2031
  • Figure 66: Europe Radiopharmaceutical Theranostics Market Value Share Analysis, by Approach, 2022 and 2031
  • Figure 67: Europe Radiopharmaceutical Theranostics Market Attractiveness Analysis, Approach, 2023-2031
  • Figure 68: Europe Radiopharmaceutical Theranostics Market Value Share Analysis, by Radiotracer Type, 2022 and 2031
  • Figure 69: Europe Radiopharmaceutical Theranostics Market Attractiveness Analysis, Radiotracer Type, 2023-2031
  • Figure 70: Europe Radiopharmaceutical Theranostics Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 71: Europe Radiopharmaceutical Theranostics Market Attractiveness Analysis, End-user, 2023-2031
  • Figure 72: Rest of the World Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 73: Rest of the World Radiopharmaceutical Theranostics Market Value Share Analysis, by Radioisotope, 2022 and 2031
  • Figure 74: Rest of the World Radiopharmaceutical Theranostics Market Attractiveness Analysis, Radioisotope, 2023-2031
  • Figure 75: Rest of the World Radiopharmaceutical Theranostics Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 76: Rest of the World Radiopharmaceutical Theranostics Market Attractiveness Analysis, Application, 2023-2031
  • Figure 77: Rest of the World Radiopharmaceutical Theranostics Market Value Share Analysis, by Source, 2022 and 2031
  • Figure 78: Rest of the World Radiopharmaceutical Theranostics Market Attractiveness Analysis, Source, 2023-2031
  • Figure 79: Rest of the World Radiopharmaceutical Theranostics Market Value Share Analysis, by Approach, 2022 and 2031
  • Figure 80: Rest of the World Radiopharmaceutical Theranostics Market Attractiveness Analysis, Approach, 2023-2031
  • Figure 81: Rest of the World Radiopharmaceutical Theranostics Market Value Share Analysis, by Radiotracer Type, 2022 and 2031
  • Figure 82: Rest of the World Radiopharmaceutical Theranostics Market Attractiveness Analysis, Radiotracer Type, 2023-2031
  • Figure 83: Rest of the World Radiopharmaceutical Theranostics Market Value Share Analysis, by End-user 2022 and 2031
  • Figure 84: Rest of the World Radiopharmaceutical Theranostics Market Attractiveness Analysis, End-user, 2023-2031